Form 4: Liquidia Grants Equity to Chief Accounting Officer

Liquidia Corp's Chief Accounting Officer, Dana Boyle, received grants of 23,728 Restricted Stock Units and 35,592 Performance Stock Units.

Summary

• Dana Boyle, Chief Accounting Officer of Liquidia Corp (LQDA), was granted 23,728 Restricted Stock Units (RSUs) and 35,592 Performance Stock Units (PSUs) on January 16, 2026.
• RSUs convert into common stock on a one-for-one basis and vest 25% on January 11, 2027, with 6.25% vesting every three months thereafter.
• PSUs also convert into common stock on a one-for-one basis and vest 25% on January 11, 2027, or the date of the FY2026 10-K filing, with 6.25% vesting every three months thereafter.
• PSU vesting is subject to a milestone condition based on net product sales revenue from YUTREPIA in 2026, as disclosed in the company's FY2026 10-K.
• Following these transactions, Dana Boyle beneficially owns 180,428 non-derivative common stock (including unvested RSUs and ESPP shares) and 35,592 derivative PSUs.

Sentiment

Score: 6

Explanation: The grants of RSUs and PSUs to a key executive are a standard compensation practice, aligning management's interests with shareholder value, particularly with performance-based vesting tied to product sales.

Positives

• Grants of 23,728 RSUs and 35,592 PSUs align the Chief Accounting Officer's interests with long-term shareholder value.
• Performance-based vesting for PSUs tied to YUTREPIA net product sales revenue in 2026 incentivizes achievement of key commercial milestones.
• The equity grants serve as a retention mechanism for a key executive.

Negatives

• Potential future dilution for existing shareholders upon vesting and conversion of RSUs and PSUs into common stock.

Risks

• The vesting of Performance Stock Units is contingent on achieving specific net product sales revenue from YUTREPIA in 2026, as disclosed in the FY2026 10-K, introducing performance risk for the executive.

Future Outlook

The vesting of Performance Stock Units is tied to the net product sales revenue of YUTREPIA in 2026, as will be disclosed in the company's FY2026 10-K, indicating a focus on future commercial success of this product.

Management Comments

• Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
• Performance stock units ("PSUs") convert into common stock on a one-for-one basis.

Industry Context

Equity grants, including RSUs and PSUs, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. They are designed to align management incentives with long-term company performance and shareholder interests, particularly in companies with significant R&D and commercialization milestones like Liquidia.

Comparison to Industry Standards

• The use of both time-based Restricted Stock Units (RSUs) and performance-based Performance Stock Units (PSUs) is a common practice in executive compensation across the biotech and pharma sectors, similar to companies like Biogen or Gilead Sciences, which often use a mix of equity awards to incentivize executives.
• Tying PSU vesting to specific product sales revenue, such as YUTREPIA in 2026, is a direct performance metric often seen in commercial-stage biopharmaceutical companies, comparable to how companies like Vertex Pharmaceuticals might incentivize sales targets for their key drugs.

Related Party Transactions

• The grant of 23,728 Restricted Stock Units and 35,592 Performance Stock Units to Dana Boyle, the Chief Accounting Officer, constitutes a related party transaction as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential future dilution upon conversion of RSUs and PSUs, but also potential benefit from incentivized executive performance, especially regarding YUTREPIA sales.
• Employees: Standard executive compensation practices can influence overall company morale and compensation structures.
• Executive (Dana Boyle): Significant increase in potential future equity ownership, aligning personal financial interests with company performance.

Next Steps

• Vesting of 25% of RSUs and PSUs on January 11, 2027.
• Subsequent quarterly vesting of 6.25% of RSUs and PSUs every three months following the Initial Vesting Date.
• Assessment of YUTREPIA net product sales revenue in 2026 for PSU vesting, to be disclosed in the FY2026 10-K.

Key Dates

Keywords

Liquidia Corp, LQDA, Form 4, Insider Transaction, Restricted Stock Units, Performance Stock Units, Executive Compensation, Equity Grant, YUTREPIA, Chief Accounting Officer, Stock Vesting